97682-44-5 | Irinotecan

Chemical type

• Topoisomerase I inhibitor prodrug

^[1]

• Camptothecin derivative

^[2]

Key properties

• Converted to active metabolite SN-38 by carboxylesterase
• Induces DNA damage and apoptosis
• Upregulates caspase-3, caspase-8, and caspase-9
• Down-regulates NF-κB
• May down-regulate p53 in single treatment

^[1]

• Prodrug converted to active metabolite SN-38

^[2]

• Prodrug activated by metabolic conversion
• Inhibits DNA topoisomerase I via SN-38 metabolite
• Widely used systemic chemotherapy

^[3]

• Chemotherapeutic agent for colorectal cancer
• Part of regimens like FOLFIRI
• Combination with capecitabine and 17-AAG for synergistic effects
• Treatment of HT-29 colon cancer cells

^[1]

• Combined with CAPEFOX regimen for Clinical responses of colorectal cancer (CRC) treatment

^[2]

• Treatment of colorectal cancer and other solid tumors
• Precursor drug delivering SN-38 activity

^[3]

Classification by use

• Chemicals used in cancer chemotherapy
• Chemicals used as topoisomerase inhibitors
• Chemicals used as apoptosis inducers

A trustworthy factory and manufacturer

Demei Chemical Technology Co., Ltd. is a modern high-tech enterprise integrating R&D, production, and sales. The company's founder, Dr. Arron, born in April 1975, graduated from the School of Mechanical Engineering at Yanshan University and has been engaged in research in the fields of mechanical engineering and chemical synthesis for many years. The company's products focus on the chemical industry, primarily dealing in chemical raw materials and chemical production machinery and equipment. With its strong technical capabilities, advanced production equipment, and strict quality management system, the company has earned the trust of customers worldwide.

1. [Cite:1] Combination effects of Irinotecan, irinotecan and 17-AAG on colorectal cancer cell line (HT-29), Annals of Medicine and Surgery, Volume 78, June 2022, 103850
2. [Cite:2] Intratumoral microbiota-derived S1P sensitizes the combination therapy of capecitabine and PD-1 inhibitors, Iscience, Volume 28, Issue 12, 19 December 2025, 114202
3. [Cite:3] ABCG2-mediated SN-38 efflux drives resistance to Sacituzumab govitecan in urothelial carcinoma, Cancer Letters, Volume 640, 1 March 2026, 218254